在澳大利亚红十字会生命之血对献血者进行常规铁蛋白检测的时代,更新铁缺乏症的诊断和管理。

IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Medical Journal of Australia Pub Date : 2024-09-03 DOI:10.5694/mja2.52429
Gary D Zhang, Daniel Johnstone, Michael F Leahy, John K Olynyk
{"title":"在澳大利亚红十字会生命之血对献血者进行常规铁蛋白检测的时代,更新铁缺乏症的诊断和管理。","authors":"Gary D Zhang,&nbsp;Daniel Johnstone,&nbsp;Michael F Leahy,&nbsp;John K Olynyk","doi":"10.5694/mja2.52429","DOIUrl":null,"url":null,"abstract":"<p>Iron deficiency is the most common micronutrient deficiency worldwide<span><sup>1</sup></span> and the predominant cause of anaemia, which affects one-quarter of the global population.<span><sup>2</sup></span></p><p>In Australia, 22.3% of women have depleted iron stores (serum ferritin level &lt; 30 μg/L), with pre-menopausal women disproportionately affected.<span><sup>3</sup></span> In contrast, 3.5% of men are iron deficient.<span><sup>3</sup></span></p><p>The Australian Red Cross Lifeblood implemented routine ferritin level testing in August 2023 for new whole blood donors (105 069 in 2023),<span><sup>4</sup></span> with expanded testing to include returning blood donors in 2024.<span><sup>5</sup></span> Donors are formally advised if their ferritin result is outside the reference intervals of 15–400 μg/L for female donors and 30–500 μg/L for male donors.<span><sup>5</sup></span> This will identify a considerable number of iron deficient adults who will be directed to their primary care physician for management. In the context of this policy change and implications for primary care, this article provides a guide for investigating and managing absolute iron deficiency.</p><p>Iron stores inadequate to meet the demands of the body result in absolute iron deficiency, which is associated with a compensatory reduction in serum hepcidin concentration to stimulate an increase in gastrointestinal iron absorption and restore homeostasis.<span><sup>6-8</sup></span> Functional iron deficiency occurs when relatively normal iron stores are unable to be released for physiological requirements due to inappropriately elevated serum hepcidin levels, as may occur in chronic inflammatory conditions, including obesity, chronic disease and neoplasia.<span><sup>6-8</sup></span> Absolute and functional iron deficiency can also co-exist.<span><sup>7</sup></span> A ferritin level below the reference interval should always be interpreted as absolute iron deficiency.</p><p>The diagnosis of iron deficiency is based on routinely available blood biomarkers as described in Box 1. Serum ferritin level cut-offs to diagnose iron deficiency vary considerably,<span><sup>9</sup></span> from less than 15 μg/L used by the World Health Organization,<span><sup>10</sup></span> which predicts absent iron stores with very high specificity,<span><sup>7</sup></span> to less than 30 μg/L commonly used in Australia.<span><sup>7, 8, 11, 12</sup></span> Although the sex-based cut-offs adopted by the Australian Red Cross Lifeblood were reportedly derived from the Royal College of Pathologists of Australasia,<span><sup>12</sup></span> there is significant concern regarding inequalities using unconventional sex-based cut-offs, with underdiagnosis and undertreatment of iron deficient women. As an acute-phase reactant, ferritin may be falsely normal or elevated in iron deficient individuals when there is concurrent inflammation, obesity, steatotic liver disease, malignancy or other chronic disease.<span><sup>6, 7, 11</sup></span> Thus, a serum ferritin level less than 70 μg/L in an individual with a concurrent inflammatory condition may suggest iron deficiency.<span><sup>10</sup></span> Transferrin saturation values less than 20% indicate low serum iron bioavailability, consistent with absolute or functional iron deficiency. The mean cell volume and mean cell haemoglobin concentration are sensitive measures for iron deficiency anaemia (IDA) when B12 or folate deficiency are absent.<span><sup>6, 11</sup></span></p><p>Further assessment must be conducted to define the underlying aetiology of iron deficiency, which can be broadly categorised into physiological, inadequate intake or absorption, blood loss, and rare genetic causes (Box 2). Factors such as age, sex and ethnicity influence the probability of different aetiologies. Although physiological causes are commonly suspected in younger individuals, the incidence of pathological causes, such as colorectal malignancy, increases with age (Box 3). Risk stratification is necessary to guide appropriate investigations. A suggested approach to a low serum ferritin result is presented in Box 4.</p><p>Physiological causes of iron deficiency predominately affect pre-menopausal women, pregnant women and growing children. Menstrual blood loss contributes significantly to iron deficiency, with iron deficiency affecting around half of women with heavy menstrual bleeding.<span><sup>6-8, 11</sup></span></p><p>Iron uptake is affected by dietary intake and absorption. Haem iron is efficiently absorbed in the duodenum, whereas non-haem iron is less efficiently absorbed and influenced by dietary composition.<span><sup>13</sup></span> Several dietary factors inhibit non-haem iron absorption (Box 2).<span><sup>13</sup></span> The ingestion of ascorbic acid (vitamin C), lactic acid (found in fermented foods) and animal meat enhances the absorption of iron.<span><sup>13</sup></span> Gastric acid, which can be impaired by medications, aids in the conversion of insoluble ferric non-haem iron to the absorbable ferrous form.<span><sup>14</sup></span> Surgical resection or bypass involving the stomach or small intestine (or both) predisposes the patient to iron deficiency due to malabsorption and reduced food intake.<span><sup>15</sup></span></p><p>Coeliac disease has a global prevalence of 0.7–1.4% and accounts for about 3% of IDA in the general population.<span><sup>16</sup></span> Serological testing for coeliac disease using serum tissue transglutaminase IgA antibody levels should be undertaken for assessment of iron deficiency.<span><sup>6, 7</sup></span> In the 2–3% of coeliac patients with IgA deficiency, an IgA level or IgG-based assay, such as deamidated gliadin peptide, should be performed.<span><sup>6, 7</sup></span> Duodenal biopsies taken when the patient is on a gluten-containing diet remains the gold standard for diagnosis of coeliac disease in Australia.</p><p>Autoimmune gastritis, generally associated with pernicious anaemia, is commonly refractory to oral iron supplementation and reported in 27% of individuals with unexplained IDA.<span><sup>17</sup></span> <i>Helicobacter pylori</i> infection is associated with iron deficiency and eradication improves iron stores, especially in cases previously refractory to oral iron supplementation.<span><sup>17</sup></span></p><p>In obesity, iron deficiency can result from reduced iron absorption.<span><sup>7</sup></span></p><p>There are also rare genetic causes of unexplained iron deficiency.<span><sup>6, 7</sup></span></p><p>Blood loss is the most common and most significant pathological cause of iron deficiency, with aetiologies described in Box 2. Gastrointestinal blood loss accounts for most cases of iron deficiency,<span><sup>6, 7, 9, 11, 18</sup></span> with bidirectional endoscopic examination detecting a potential gastrointestinal bleeding cause in two-thirds of men and post-menopausal women with IDA. Bidirectional endoscopic examination should be routinely considered for all adults with iron deficiency as the technique shows a detection rate of 11% for gastrointestinal malignancy and 9% for colorectal malignancy.<span><sup>6-9</sup></span> Faecal occult blood testing is used for asymptomatic average-risk bowel cancer screening and should not guide iron deficiency investigations.<span><sup>6, 7</sup></span> Small intestine investigation, predominantly with capsule endoscopy, may be considered in recurrent or refractory IDA following unremarkable bidirectional endoscopy results.<span><sup>19</sup></span> When colonoscopy is contraindicated, computed tomography colonography can help rule out colorectal lesions larger than or equal to 6 mm, but cannot provide histopathological diagnosis.<span><sup>7, 20</sup></span> Medications can exacerbate blood loss, particularly non-steroidal anti-inflammatory drugs and anti-thrombotics.<span><sup>6-8</sup></span> Urinalysis is recommended to screen for microscopic haematuria, although this test is not sensitive for urological malignancies.<span><sup>6</sup></span> Stool investigations for intestinal parasitic infections can be done for at-risk individuals with exposure to endemic regions.<span><sup>8</sup></span> Frequent whole blood donation can result in iron deficiency.<span><sup>11</sup></span></p><p>Iron supplementation, available in oral or parenteral forms, is required for all individuals with IDA and should be started promptly to replace body iron stores and resolve symptoms. Iron replacement for non-anaemic iron deficiency improves symptoms and clinical outcomes.<span><sup>6, 7</sup></span> Iron-deplete women with serum ferritin levels of 15–30 μg/L will not be identified through the Australian Red Cross Lifeblood testing, although may benefit from iron replacement. Blood transfusion with restrictive targets should be reserved for severe symptomatic anaemia and symptoms of reduced oxygen-carrying capacity with cardiovascular compromise or ongoing blood loss, when iron replacement alone is insufficient.<span><sup>6</sup></span> Increasing dietary iron intake alone is insufficient for iron deficiency, although should be optimised for secondary prevention.</p><p>Oral iron supplementation is considered first-line therapy. Numerous formulations are available (Box 5). Multivitamins or supplements with low iron concentrations and modified-release formulations are ineffective. Ferrous iron taken on an empty stomach ensures optimal absorption. Oral iron polymaltose is not dependent on gastric acidity or vitamin C, is best taken with food, and represents an alternative preparation.<span><sup>7</sup></span> Elemental oral iron doses of larger than or equal to 60 mg reduce the absorption of subsequent oral doses.<span><sup>21</sup></span> A single 200 mg dose taken on alternate days results in about twice the absorption of a single 100 mg daily dose.<span><sup>22</sup></span> Twice-daily dosing has the lowest absorption.<span><sup>23</sup></span> Alternate day single doses are associated with significantly higher iron absorption and lower hepcidin induction compared with daily dosing,<span><sup>23</sup></span> and may have reduced gastrointestinal adverse events,<span><sup>24</sup></span> compliance concerns and therapy cessation.<span><sup>7</sup></span></p><p>Supplementation with intravenous iron results in a faster haemoglobin concentration increase compared with oral iron supplementation, although haemoglobin levels at 12 weeks are similar.<span><sup>6-8, 11</sup></span> The indications, available formulations, duration of administration and maximum dosage are described in Box 6. Current parenteral iron formulations are well tolerated and suitable for administration in primary care. Monitoring is generally advised despite no associations with serious infusion reactions.<span><sup>25</sup></span> Parenteral iron should be avoided in patients with active infection.<span><sup>25</sup></span> Skin staining can occur with extravasation. Hypophosphataemia is most common after ferric carboxymaltose, with the condition usually asymptomatic, and recovery expected over eight to ten weeks.<span><sup>7</sup></span> Routine measurement of phosphate is not recommended if asymptomatic. Intramuscular administration of iron is not routinely recommended.</p><p>After commencing iron therapy, haemoglobin levels should be checked within two to four weeks for an expected rise of more than or equal to 10 g/L.<span><sup>6</sup></span> Serum ferritin and haemoglobin levels should be measured monthly for the first three months, targeting serum ferritin normalisation or a haemoglobin increase of 20 g/L in IDA.<span><sup>6</sup></span> Oral iron should be continued for at least three months following an effective response; adherence and impaired iron uptake should be considered with inadequate responses. Thereafter, ferritin and haemoglobin levels should be monitored every three to six months for 12 months after treatment of iron deficiency and its underlying cause.<span><sup>6</sup></span> Iron supplementation should be restarted if levels are not maintained, and further investigations considered.</p><p>Implementation of routine ferritin testing by the Australian Red Cross Lifeblood will increase detection of iron deficiency among blood donors. Low serum ferritin levels are diagnostic of absolute iron deficiency and require clinical evaluation. The aetiologies of iron deficiency can be broadly categorised into physiological, inadequate dietary intake or absorption, blood loss, and rare genetic causes. Risk stratification of individuals should be considered to target investigations. Following the diagnosis of iron deficiency, iron replacement should be started early.</p><p>No relevant disclosures.</p><p>Not commissioned; externally peer reviewed.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 7","pages":"360-364"},"PeriodicalIF":6.7000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52429","citationCount":"0","resultStr":"{\"title\":\"Updating the diagnosis and management of iron deficiency in the era of routine ferritin testing of blood donors by Australian Red Cross Lifeblood\",\"authors\":\"Gary D Zhang,&nbsp;Daniel Johnstone,&nbsp;Michael F Leahy,&nbsp;John K Olynyk\",\"doi\":\"10.5694/mja2.52429\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Iron deficiency is the most common micronutrient deficiency worldwide<span><sup>1</sup></span> and the predominant cause of anaemia, which affects one-quarter of the global population.<span><sup>2</sup></span></p><p>In Australia, 22.3% of women have depleted iron stores (serum ferritin level &lt; 30 μg/L), with pre-menopausal women disproportionately affected.<span><sup>3</sup></span> In contrast, 3.5% of men are iron deficient.<span><sup>3</sup></span></p><p>The Australian Red Cross Lifeblood implemented routine ferritin level testing in August 2023 for new whole blood donors (105 069 in 2023),<span><sup>4</sup></span> with expanded testing to include returning blood donors in 2024.<span><sup>5</sup></span> Donors are formally advised if their ferritin result is outside the reference intervals of 15–400 μg/L for female donors and 30–500 μg/L for male donors.<span><sup>5</sup></span> This will identify a considerable number of iron deficient adults who will be directed to their primary care physician for management. In the context of this policy change and implications for primary care, this article provides a guide for investigating and managing absolute iron deficiency.</p><p>Iron stores inadequate to meet the demands of the body result in absolute iron deficiency, which is associated with a compensatory reduction in serum hepcidin concentration to stimulate an increase in gastrointestinal iron absorption and restore homeostasis.<span><sup>6-8</sup></span> Functional iron deficiency occurs when relatively normal iron stores are unable to be released for physiological requirements due to inappropriately elevated serum hepcidin levels, as may occur in chronic inflammatory conditions, including obesity, chronic disease and neoplasia.<span><sup>6-8</sup></span> Absolute and functional iron deficiency can also co-exist.<span><sup>7</sup></span> A ferritin level below the reference interval should always be interpreted as absolute iron deficiency.</p><p>The diagnosis of iron deficiency is based on routinely available blood biomarkers as described in Box 1. Serum ferritin level cut-offs to diagnose iron deficiency vary considerably,<span><sup>9</sup></span> from less than 15 μg/L used by the World Health Organization,<span><sup>10</sup></span> which predicts absent iron stores with very high specificity,<span><sup>7</sup></span> to less than 30 μg/L commonly used in Australia.<span><sup>7, 8, 11, 12</sup></span> Although the sex-based cut-offs adopted by the Australian Red Cross Lifeblood were reportedly derived from the Royal College of Pathologists of Australasia,<span><sup>12</sup></span> there is significant concern regarding inequalities using unconventional sex-based cut-offs, with underdiagnosis and undertreatment of iron deficient women. As an acute-phase reactant, ferritin may be falsely normal or elevated in iron deficient individuals when there is concurrent inflammation, obesity, steatotic liver disease, malignancy or other chronic disease.<span><sup>6, 7, 11</sup></span> Thus, a serum ferritin level less than 70 μg/L in an individual with a concurrent inflammatory condition may suggest iron deficiency.<span><sup>10</sup></span> Transferrin saturation values less than 20% indicate low serum iron bioavailability, consistent with absolute or functional iron deficiency. The mean cell volume and mean cell haemoglobin concentration are sensitive measures for iron deficiency anaemia (IDA) when B12 or folate deficiency are absent.<span><sup>6, 11</sup></span></p><p>Further assessment must be conducted to define the underlying aetiology of iron deficiency, which can be broadly categorised into physiological, inadequate intake or absorption, blood loss, and rare genetic causes (Box 2). Factors such as age, sex and ethnicity influence the probability of different aetiologies. Although physiological causes are commonly suspected in younger individuals, the incidence of pathological causes, such as colorectal malignancy, increases with age (Box 3). Risk stratification is necessary to guide appropriate investigations. A suggested approach to a low serum ferritin result is presented in Box 4.</p><p>Physiological causes of iron deficiency predominately affect pre-menopausal women, pregnant women and growing children. Menstrual blood loss contributes significantly to iron deficiency, with iron deficiency affecting around half of women with heavy menstrual bleeding.<span><sup>6-8, 11</sup></span></p><p>Iron uptake is affected by dietary intake and absorption. Haem iron is efficiently absorbed in the duodenum, whereas non-haem iron is less efficiently absorbed and influenced by dietary composition.<span><sup>13</sup></span> Several dietary factors inhibit non-haem iron absorption (Box 2).<span><sup>13</sup></span> The ingestion of ascorbic acid (vitamin C), lactic acid (found in fermented foods) and animal meat enhances the absorption of iron.<span><sup>13</sup></span> Gastric acid, which can be impaired by medications, aids in the conversion of insoluble ferric non-haem iron to the absorbable ferrous form.<span><sup>14</sup></span> Surgical resection or bypass involving the stomach or small intestine (or both) predisposes the patient to iron deficiency due to malabsorption and reduced food intake.<span><sup>15</sup></span></p><p>Coeliac disease has a global prevalence of 0.7–1.4% and accounts for about 3% of IDA in the general population.<span><sup>16</sup></span> Serological testing for coeliac disease using serum tissue transglutaminase IgA antibody levels should be undertaken for assessment of iron deficiency.<span><sup>6, 7</sup></span> In the 2–3% of coeliac patients with IgA deficiency, an IgA level or IgG-based assay, such as deamidated gliadin peptide, should be performed.<span><sup>6, 7</sup></span> Duodenal biopsies taken when the patient is on a gluten-containing diet remains the gold standard for diagnosis of coeliac disease in Australia.</p><p>Autoimmune gastritis, generally associated with pernicious anaemia, is commonly refractory to oral iron supplementation and reported in 27% of individuals with unexplained IDA.<span><sup>17</sup></span> <i>Helicobacter pylori</i> infection is associated with iron deficiency and eradication improves iron stores, especially in cases previously refractory to oral iron supplementation.<span><sup>17</sup></span></p><p>In obesity, iron deficiency can result from reduced iron absorption.<span><sup>7</sup></span></p><p>There are also rare genetic causes of unexplained iron deficiency.<span><sup>6, 7</sup></span></p><p>Blood loss is the most common and most significant pathological cause of iron deficiency, with aetiologies described in Box 2. Gastrointestinal blood loss accounts for most cases of iron deficiency,<span><sup>6, 7, 9, 11, 18</sup></span> with bidirectional endoscopic examination detecting a potential gastrointestinal bleeding cause in two-thirds of men and post-menopausal women with IDA. Bidirectional endoscopic examination should be routinely considered for all adults with iron deficiency as the technique shows a detection rate of 11% for gastrointestinal malignancy and 9% for colorectal malignancy.<span><sup>6-9</sup></span> Faecal occult blood testing is used for asymptomatic average-risk bowel cancer screening and should not guide iron deficiency investigations.<span><sup>6, 7</sup></span> Small intestine investigation, predominantly with capsule endoscopy, may be considered in recurrent or refractory IDA following unremarkable bidirectional endoscopy results.<span><sup>19</sup></span> When colonoscopy is contraindicated, computed tomography colonography can help rule out colorectal lesions larger than or equal to 6 mm, but cannot provide histopathological diagnosis.<span><sup>7, 20</sup></span> Medications can exacerbate blood loss, particularly non-steroidal anti-inflammatory drugs and anti-thrombotics.<span><sup>6-8</sup></span> Urinalysis is recommended to screen for microscopic haematuria, although this test is not sensitive for urological malignancies.<span><sup>6</sup></span> Stool investigations for intestinal parasitic infections can be done for at-risk individuals with exposure to endemic regions.<span><sup>8</sup></span> Frequent whole blood donation can result in iron deficiency.<span><sup>11</sup></span></p><p>Iron supplementation, available in oral or parenteral forms, is required for all individuals with IDA and should be started promptly to replace body iron stores and resolve symptoms. Iron replacement for non-anaemic iron deficiency improves symptoms and clinical outcomes.<span><sup>6, 7</sup></span> Iron-deplete women with serum ferritin levels of 15–30 μg/L will not be identified through the Australian Red Cross Lifeblood testing, although may benefit from iron replacement. Blood transfusion with restrictive targets should be reserved for severe symptomatic anaemia and symptoms of reduced oxygen-carrying capacity with cardiovascular compromise or ongoing blood loss, when iron replacement alone is insufficient.<span><sup>6</sup></span> Increasing dietary iron intake alone is insufficient for iron deficiency, although should be optimised for secondary prevention.</p><p>Oral iron supplementation is considered first-line therapy. Numerous formulations are available (Box 5). Multivitamins or supplements with low iron concentrations and modified-release formulations are ineffective. Ferrous iron taken on an empty stomach ensures optimal absorption. Oral iron polymaltose is not dependent on gastric acidity or vitamin C, is best taken with food, and represents an alternative preparation.<span><sup>7</sup></span> Elemental oral iron doses of larger than or equal to 60 mg reduce the absorption of subsequent oral doses.<span><sup>21</sup></span> A single 200 mg dose taken on alternate days results in about twice the absorption of a single 100 mg daily dose.<span><sup>22</sup></span> Twice-daily dosing has the lowest absorption.<span><sup>23</sup></span> Alternate day single doses are associated with significantly higher iron absorption and lower hepcidin induction compared with daily dosing,<span><sup>23</sup></span> and may have reduced gastrointestinal adverse events,<span><sup>24</sup></span> compliance concerns and therapy cessation.<span><sup>7</sup></span></p><p>Supplementation with intravenous iron results in a faster haemoglobin concentration increase compared with oral iron supplementation, although haemoglobin levels at 12 weeks are similar.<span><sup>6-8, 11</sup></span> The indications, available formulations, duration of administration and maximum dosage are described in Box 6. Current parenteral iron formulations are well tolerated and suitable for administration in primary care. Monitoring is generally advised despite no associations with serious infusion reactions.<span><sup>25</sup></span> Parenteral iron should be avoided in patients with active infection.<span><sup>25</sup></span> Skin staining can occur with extravasation. Hypophosphataemia is most common after ferric carboxymaltose, with the condition usually asymptomatic, and recovery expected over eight to ten weeks.<span><sup>7</sup></span> Routine measurement of phosphate is not recommended if asymptomatic. Intramuscular administration of iron is not routinely recommended.</p><p>After commencing iron therapy, haemoglobin levels should be checked within two to four weeks for an expected rise of more than or equal to 10 g/L.<span><sup>6</sup></span> Serum ferritin and haemoglobin levels should be measured monthly for the first three months, targeting serum ferritin normalisation or a haemoglobin increase of 20 g/L in IDA.<span><sup>6</sup></span> Oral iron should be continued for at least three months following an effective response; adherence and impaired iron uptake should be considered with inadequate responses. Thereafter, ferritin and haemoglobin levels should be monitored every three to six months for 12 months after treatment of iron deficiency and its underlying cause.<span><sup>6</sup></span> Iron supplementation should be restarted if levels are not maintained, and further investigations considered.</p><p>Implementation of routine ferritin testing by the Australian Red Cross Lifeblood will increase detection of iron deficiency among blood donors. Low serum ferritin levels are diagnostic of absolute iron deficiency and require clinical evaluation. The aetiologies of iron deficiency can be broadly categorised into physiological, inadequate dietary intake or absorption, blood loss, and rare genetic causes. Risk stratification of individuals should be considered to target investigations. Following the diagnosis of iron deficiency, iron replacement should be started early.</p><p>No relevant disclosures.</p><p>Not commissioned; externally peer reviewed.</p>\",\"PeriodicalId\":18214,\"journal\":{\"name\":\"Medical Journal of Australia\",\"volume\":\"221 7\",\"pages\":\"360-364\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2024-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52429\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Journal of Australia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.5694/mja2.52429\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of Australia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.5694/mja2.52429","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

开始铁剂治疗后,应在 2 到 4 周内检查血红蛋白水平,预计血红蛋白水平会上升 10 克/升以上。6 在最初的三个月中,应每月测量血清铁蛋白和血红蛋白水平,目标是血清铁蛋白恢复正常或 IDA 患者的血红蛋白上升 20 克/升。6 在出现有效反应后,应继续口服铁剂至少三个月;如果反应不充分,则应考虑是否存在依从性和铁吸收障碍。此后,在治疗缺铁症及其根本原因后的 12 个月内,应每隔三到六个月监测一次铁蛋白和血红蛋白水平。6 如果铁蛋白和血红蛋白水平不能保持稳定,则应重新开始补充铁剂,并考虑进行进一步检查。澳大利亚红十字会生命之血实施的常规铁蛋白检测将提高对献血者缺铁症的检测率。血清铁蛋白水平低可诊断为绝对缺铁,需要进行临床评估。缺铁的病因可大致分为生理性、饮食摄入或吸收不足、失血和罕见的遗传原因。应考虑对个人进行风险分层,以便有针对性地进行检查。确诊缺铁症后,应尽早开始补铁。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Updating the diagnosis and management of iron deficiency in the era of routine ferritin testing of blood donors by Australian Red Cross Lifeblood

Iron deficiency is the most common micronutrient deficiency worldwide1 and the predominant cause of anaemia, which affects one-quarter of the global population.2

In Australia, 22.3% of women have depleted iron stores (serum ferritin level < 30 μg/L), with pre-menopausal women disproportionately affected.3 In contrast, 3.5% of men are iron deficient.3

The Australian Red Cross Lifeblood implemented routine ferritin level testing in August 2023 for new whole blood donors (105 069 in 2023),4 with expanded testing to include returning blood donors in 2024.5 Donors are formally advised if their ferritin result is outside the reference intervals of 15–400 μg/L for female donors and 30–500 μg/L for male donors.5 This will identify a considerable number of iron deficient adults who will be directed to their primary care physician for management. In the context of this policy change and implications for primary care, this article provides a guide for investigating and managing absolute iron deficiency.

Iron stores inadequate to meet the demands of the body result in absolute iron deficiency, which is associated with a compensatory reduction in serum hepcidin concentration to stimulate an increase in gastrointestinal iron absorption and restore homeostasis.6-8 Functional iron deficiency occurs when relatively normal iron stores are unable to be released for physiological requirements due to inappropriately elevated serum hepcidin levels, as may occur in chronic inflammatory conditions, including obesity, chronic disease and neoplasia.6-8 Absolute and functional iron deficiency can also co-exist.7 A ferritin level below the reference interval should always be interpreted as absolute iron deficiency.

The diagnosis of iron deficiency is based on routinely available blood biomarkers as described in Box 1. Serum ferritin level cut-offs to diagnose iron deficiency vary considerably,9 from less than 15 μg/L used by the World Health Organization,10 which predicts absent iron stores with very high specificity,7 to less than 30 μg/L commonly used in Australia.7, 8, 11, 12 Although the sex-based cut-offs adopted by the Australian Red Cross Lifeblood were reportedly derived from the Royal College of Pathologists of Australasia,12 there is significant concern regarding inequalities using unconventional sex-based cut-offs, with underdiagnosis and undertreatment of iron deficient women. As an acute-phase reactant, ferritin may be falsely normal or elevated in iron deficient individuals when there is concurrent inflammation, obesity, steatotic liver disease, malignancy or other chronic disease.6, 7, 11 Thus, a serum ferritin level less than 70 μg/L in an individual with a concurrent inflammatory condition may suggest iron deficiency.10 Transferrin saturation values less than 20% indicate low serum iron bioavailability, consistent with absolute or functional iron deficiency. The mean cell volume and mean cell haemoglobin concentration are sensitive measures for iron deficiency anaemia (IDA) when B12 or folate deficiency are absent.6, 11

Further assessment must be conducted to define the underlying aetiology of iron deficiency, which can be broadly categorised into physiological, inadequate intake or absorption, blood loss, and rare genetic causes (Box 2). Factors such as age, sex and ethnicity influence the probability of different aetiologies. Although physiological causes are commonly suspected in younger individuals, the incidence of pathological causes, such as colorectal malignancy, increases with age (Box 3). Risk stratification is necessary to guide appropriate investigations. A suggested approach to a low serum ferritin result is presented in Box 4.

Physiological causes of iron deficiency predominately affect pre-menopausal women, pregnant women and growing children. Menstrual blood loss contributes significantly to iron deficiency, with iron deficiency affecting around half of women with heavy menstrual bleeding.6-8, 11

Iron uptake is affected by dietary intake and absorption. Haem iron is efficiently absorbed in the duodenum, whereas non-haem iron is less efficiently absorbed and influenced by dietary composition.13 Several dietary factors inhibit non-haem iron absorption (Box 2).13 The ingestion of ascorbic acid (vitamin C), lactic acid (found in fermented foods) and animal meat enhances the absorption of iron.13 Gastric acid, which can be impaired by medications, aids in the conversion of insoluble ferric non-haem iron to the absorbable ferrous form.14 Surgical resection or bypass involving the stomach or small intestine (or both) predisposes the patient to iron deficiency due to malabsorption and reduced food intake.15

Coeliac disease has a global prevalence of 0.7–1.4% and accounts for about 3% of IDA in the general population.16 Serological testing for coeliac disease using serum tissue transglutaminase IgA antibody levels should be undertaken for assessment of iron deficiency.6, 7 In the 2–3% of coeliac patients with IgA deficiency, an IgA level or IgG-based assay, such as deamidated gliadin peptide, should be performed.6, 7 Duodenal biopsies taken when the patient is on a gluten-containing diet remains the gold standard for diagnosis of coeliac disease in Australia.

Autoimmune gastritis, generally associated with pernicious anaemia, is commonly refractory to oral iron supplementation and reported in 27% of individuals with unexplained IDA.17 Helicobacter pylori infection is associated with iron deficiency and eradication improves iron stores, especially in cases previously refractory to oral iron supplementation.17

In obesity, iron deficiency can result from reduced iron absorption.7

There are also rare genetic causes of unexplained iron deficiency.6, 7

Blood loss is the most common and most significant pathological cause of iron deficiency, with aetiologies described in Box 2. Gastrointestinal blood loss accounts for most cases of iron deficiency,6, 7, 9, 11, 18 with bidirectional endoscopic examination detecting a potential gastrointestinal bleeding cause in two-thirds of men and post-menopausal women with IDA. Bidirectional endoscopic examination should be routinely considered for all adults with iron deficiency as the technique shows a detection rate of 11% for gastrointestinal malignancy and 9% for colorectal malignancy.6-9 Faecal occult blood testing is used for asymptomatic average-risk bowel cancer screening and should not guide iron deficiency investigations.6, 7 Small intestine investigation, predominantly with capsule endoscopy, may be considered in recurrent or refractory IDA following unremarkable bidirectional endoscopy results.19 When colonoscopy is contraindicated, computed tomography colonography can help rule out colorectal lesions larger than or equal to 6 mm, but cannot provide histopathological diagnosis.7, 20 Medications can exacerbate blood loss, particularly non-steroidal anti-inflammatory drugs and anti-thrombotics.6-8 Urinalysis is recommended to screen for microscopic haematuria, although this test is not sensitive for urological malignancies.6 Stool investigations for intestinal parasitic infections can be done for at-risk individuals with exposure to endemic regions.8 Frequent whole blood donation can result in iron deficiency.11

Iron supplementation, available in oral or parenteral forms, is required for all individuals with IDA and should be started promptly to replace body iron stores and resolve symptoms. Iron replacement for non-anaemic iron deficiency improves symptoms and clinical outcomes.6, 7 Iron-deplete women with serum ferritin levels of 15–30 μg/L will not be identified through the Australian Red Cross Lifeblood testing, although may benefit from iron replacement. Blood transfusion with restrictive targets should be reserved for severe symptomatic anaemia and symptoms of reduced oxygen-carrying capacity with cardiovascular compromise or ongoing blood loss, when iron replacement alone is insufficient.6 Increasing dietary iron intake alone is insufficient for iron deficiency, although should be optimised for secondary prevention.

Oral iron supplementation is considered first-line therapy. Numerous formulations are available (Box 5). Multivitamins or supplements with low iron concentrations and modified-release formulations are ineffective. Ferrous iron taken on an empty stomach ensures optimal absorption. Oral iron polymaltose is not dependent on gastric acidity or vitamin C, is best taken with food, and represents an alternative preparation.7 Elemental oral iron doses of larger than or equal to 60 mg reduce the absorption of subsequent oral doses.21 A single 200 mg dose taken on alternate days results in about twice the absorption of a single 100 mg daily dose.22 Twice-daily dosing has the lowest absorption.23 Alternate day single doses are associated with significantly higher iron absorption and lower hepcidin induction compared with daily dosing,23 and may have reduced gastrointestinal adverse events,24 compliance concerns and therapy cessation.7

Supplementation with intravenous iron results in a faster haemoglobin concentration increase compared with oral iron supplementation, although haemoglobin levels at 12 weeks are similar.6-8, 11 The indications, available formulations, duration of administration and maximum dosage are described in Box 6. Current parenteral iron formulations are well tolerated and suitable for administration in primary care. Monitoring is generally advised despite no associations with serious infusion reactions.25 Parenteral iron should be avoided in patients with active infection.25 Skin staining can occur with extravasation. Hypophosphataemia is most common after ferric carboxymaltose, with the condition usually asymptomatic, and recovery expected over eight to ten weeks.7 Routine measurement of phosphate is not recommended if asymptomatic. Intramuscular administration of iron is not routinely recommended.

After commencing iron therapy, haemoglobin levels should be checked within two to four weeks for an expected rise of more than or equal to 10 g/L.6 Serum ferritin and haemoglobin levels should be measured monthly for the first three months, targeting serum ferritin normalisation or a haemoglobin increase of 20 g/L in IDA.6 Oral iron should be continued for at least three months following an effective response; adherence and impaired iron uptake should be considered with inadequate responses. Thereafter, ferritin and haemoglobin levels should be monitored every three to six months for 12 months after treatment of iron deficiency and its underlying cause.6 Iron supplementation should be restarted if levels are not maintained, and further investigations considered.

Implementation of routine ferritin testing by the Australian Red Cross Lifeblood will increase detection of iron deficiency among blood donors. Low serum ferritin levels are diagnostic of absolute iron deficiency and require clinical evaluation. The aetiologies of iron deficiency can be broadly categorised into physiological, inadequate dietary intake or absorption, blood loss, and rare genetic causes. Risk stratification of individuals should be considered to target investigations. Following the diagnosis of iron deficiency, iron replacement should be started early.

No relevant disclosures.

Not commissioned; externally peer reviewed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Journal of Australia
Medical Journal of Australia 医学-医学:内科
CiteScore
9.40
自引率
5.30%
发文量
410
审稿时长
3-8 weeks
期刊介绍: The Medical Journal of Australia (MJA) stands as Australia's foremost general medical journal, leading the dissemination of high-quality research and commentary to shape health policy and influence medical practices within the country. Under the leadership of Professor Virginia Barbour, the expert editorial team at MJA is dedicated to providing authors with a constructive and collaborative peer-review and publication process. Established in 1914, the MJA has evolved into a modern journal that upholds its founding values, maintaining a commitment to supporting the medical profession by delivering high-quality and pertinent information essential to medical practice.
期刊最新文献
Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life-threatening pathogen within Australian communities. Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life-threatening pathogen within Australian communities. Setting the standard: no LGBTI+ health equity without data equity. Scabies: a clinical update. The Future Healthy Countdown 2030 consensus statement: core policy actions and measures to achieve improvements in the health and wellbeing of children, young people and future generations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1